- Adjuvant chemotherapy (ACT) was not associated with improved OS or cancer-specific survival in patients with completely resected stage IB NSCLC, even in patients with larger tumors.
Why this matters
- ACT is recommended for patients with resected stage II-III NSCLC, but guidelines offer competing recommendations in stage IB disease.
- 1005 patients with completely resected stage IB (T2aN0M0) NSCLC.
- Funding: None.
- 20.1% (n=202) received ACT, with nearly 90% of those receiving ≥3 cycles.
- After propensity matching of 196 patient pairs, ACT was not associated with improved OS (HR, 1.058; P=0.858), DFS (HR, 0.956; P=.845), cancer-specific OS (subHR, 1.000; P=1.000), or cancer-specific DFS (subHR, 0.920; P=.720).
- After propensity matching, ACT was not associated with better OS, regardless of tumor size (tumors
- Retrospective study.
- Chemotherapy regimens were not consistent.